# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amge...
DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy ...
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...
- Reuters
- Morgan Stanley Conf
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...
Jason Snipe of Odyssey Capital Advisors likes Intuit Inc., after the company beat on the top and bottom lines, but missed on gu...